PDMR Dealing / Grant of Share Options

Oxford BioDynamics PLC

18 September 2026

 

18 September 2026 

Oxford BioDynamics Plc

("OBD" or the "Company")

PDMR Dealing / Grant of Share Options

Oxford BioDynamics Plc (AIM: OBD, the Company), the 3D Genomics Company, announces that it has today granted a total of 1,008,068,322 options (“Options”) over its ordinary shares of 0.1 pence each (“Ordinary Shares”), to Chief Executive Officer Richard Compton.

The options were granted under the Company’s 2016 Employee Share Option Plan with exercise prices and vesting dates as shown in the table below.

Number of options	Exercise price (p)	Premium over closing mid-market price on 17 September 2026	Vesting dates
336,022,774	0.115	-	12 equal tranches, one month to twelve months from today’s date
336,022,774	0.1725	50%	12 equal tranches, between 13 and 24 months from today’s date
336,022,774	0.23	100%	12 equal tranches, between 25 and 36 months from today’s date

Options will be exercisable at any time from 18 September 2027 upon vesting. Thereafter, the Options, once vested, will remain exercisable up to and including the tenth anniversary of the date of grant.

Following the grant of Options, Richard Compton’s interest in the Company will comprise:

Shareholding	Percentage of current issued share capital	Option of over Ordinary Shares	Percentage of current issued share capital
300,000,000	2.23%	1,008,068,322	7.50%

The notification below, made in accordance with the requirements of UK Market Abuse Regulation, provide further details:

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Richard Compton
2	Reason for the notification
a)	Position/status	Chief Executive Officer
b)	Initial notification/ Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Oxford BioDynamics Plc
b)	LEI	2138005Y1TK258O5U928
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary Shares of 0.1 pence each ISIN:   GB00BD5H8572
b)	Nature of the transaction	Grant of share options
c)	Price(s) and volume(s)	336,022,774 ordinary shares at an exercise price of 0.115 pence per share 336,022,774 ordinary shares at an exercise price of 0.1725 pence per share 336,022,774 ordinary shares at an exercise price of 0.23 pence per share
d)	Aggregated information - Aggregated volume - Price	N/A
e)	Date of the transaction	18 September 2026
f)	Place of the transaction	Outside a trading venue

-Ends-

For further information please contact:

Oxford BioDynamics Plc    [phone]

Richard Compton, CEO

Paul Stockdale, CFO

Singer Capital Markets – Nominated Adviser and Broker

Alex Bond / Russell Cook / Anastassiya Eley

[phone]

OAK Securities – Joint Broker

Matthew Clarke / Jerry Keen

[phone]

Camarco – Financial PR

Marc Cohen / Sukaina Virji / Tilly Butcher / Fergus Young

[phone] / [e-mail]

Notes for Editors

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD), the 3D Genomics Company, is an international biotechnology company, advancing personalised healthcare through precision clinical diagnostic tests and EpiSwitch Orion, a cloud-based 3D genomics platform that transforms existing datasets into actionable insights for pharma and biotech partners.

Currently OBD has two commercially available products: the EpiSwitch PSE (EpiSwitch Prostate Cancer Detection Test) and EpiSwitch CiRT (Checkpoint Inhibitor Response Test) blood tests. PSE boosts the predictive accuracy of a PSA test from 55% to 94% when testing the presence or absence of prostate cancer. CiRT is a highly accurate (85%) predictive response test to immuno-oncology checkpoint inhibitor treatments.

The tests are based on OBD's proprietary 3D genomic biomarker platform, EpiSwitch, which enables screening, evaluation, validation and monitoring of biomarkers to diagnose patients or determine how individuals might respond to a disease or treatment.

The Company's recently launched proprietary AI predictive platform, EpiSwitch® Orion, makes the Company's knowledgebase and analytical tools available to researchers and partners, allowing them to generate insights into 3D regulatory biology from existing datasets. EpiSwitch Orion is a cloud-based 3D genomics platform that enables pharmaceutical partners to transform standard sequencing data - including legacy whole genome datasets - into actionable discovery insights in hours rather than months. By revealing the genome's 3D architecture, EpiSwitch Orion illuminates the 90-95% of disease-associated variants in non-coding regions that traditional NGS and GWAS approaches cannot decipher, bridging the gap between statistical associations and druggable therapeutic targets. The platform is supported by the world's largest curated 3D genomics knowledgebase, featuring over 1.5 billion data points and 15 million high-confidence genomic connections validated across 18,000+ patient samples in more than 40 diseases - a foundation built over nearly two decades that enables partners to identify targets, build predictive classifier models, and design precision interventions at unprecedented speed. 

OBD's clinical smart tests have the potential to be used across a broader range of indications, and new tests are being developed in the areas of oncology, neurology, inflammation, hepatology and animal health.

Since inception, the Company has participated in more than 40 collaborations with pharmaceutical and academic partners, including Pfizer, EMD Serono, Genentech, Roche, Biogen, Mayo Clinic, Massachusetts General Hospital and Mitsubishi Tanabe Pharma America, and has been awarded funding through the US Foundation for the National Institutes of Health's Partnership for Accelerating Cancer Therapies programme and the EU-funded HIPPOCRATES consortium in psoriatic arthritis.

The Company's headquarters and UK laboratories are in Oxford, UK. Its US operations and clinical laboratory are in Maryland, USA, along with a reference laboratory in Penang, Malaysia.

OBD is listed on the London Stock Exchange's AIM (LSE: OBD). For more information, please visit the Company's website, www.oxfordbiodynamics.com, X (@OxBioDynamics) or LinkedIn.

 

END